Literature DB >> 24283841

Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?

Lais Teodoro da Silva1, Alessandra Pontillo, Wanessa Cardoso da Silva, Alexandre de Almeida, Alberto José da Silva Duarte, Telma Miyuki Oshiro.   

Abstract

AIMS: HIV-1 expanded in an allogenic system (Al-HIV) represents a cheaper and faster alternative to the autologous virus (Au-HIV) as an antigen in anti-HIV immunotherapy. In this study, chemically inactivated HIV-1 obtained through autologous or allogenic systems were compared. PATIENTS &
METHODS: Au-HIV and Al-HIV obtained from cultures of peripheral blood mononuclear cells from 11 HIV(+) individuals were tested for virus production, yield and time of culture, and their ability to elicit a specific immune response in vitro.
RESULTS: The allogenic system was more efficient than the autologous system. Dendritic cells pulsed with Au-HIV and Al-HIV presented a similar phenotypic profile, but only Al-HIV induced a significant increase in IFN-γ(+) lymphocytes.
CONCLUSION: The use of an allogenic system displays several advantages in terms of cell manipulation, time and cost of culture, and immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24283841     DOI: 10.2217/imt.13.136

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  1 in total

1.  Phenotypic and functional profile of IFN-α-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals.

Authors:  Bruna Tereso Santillo; Denise da Silva Reis; Laís Teodoro da Silva; Nathalia Teixeira Romani; Alberto José da Silva Duarte; Telma Miyuki Oshiro
Journal:  Hum Vaccin Immunother       Date:  2018-12-20       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.